source
- AstraZeneca’s GLP-1 obesity pill shows 10.5% average weight loss after six months in Phase 2 trialAstraZeneca reported data from its Phase 2 study of a GLP-1 based oral obesity treatment. The trial showed participants lost an average of 10.5% of body weight after six months of therapy. The re…
- Incyte to acquire Vega Therapeutics for up to $2 billion, securing late-stage von Willebrand disease drugIncyte announced it will purchase Vega Therapeutics, a unit of Star Therapeutics, for $1.25 billion in cash with the possibility of receiving up to $750 million more if future sales targets are met…